君正集團(601216.SH):拉薩盛泰擬認購大安製藥新增出資3.57億元
格隆匯2月17日丨君正集團(601216.SH)公佈,公司全資控股公司拉薩經濟技術開發區盛泰信息科技發展有限公司(以下簡稱“拉薩盛泰”)擬以現金方式認購河北大安製藥有限公司(以下簡稱“大安製藥”)新增出資3.57億元,對應投資金額為11.22億元。
截至目前,大安製藥註冊資本為6.54億元人民幣,大安製藥的前次增資尚未完成。前次增資及本次增資完成後,大安製藥的註冊資本將增加至11.46億元,佔大安製藥本次增資擴股後註冊資本的31.17%。本次交易中博暉創新、杜江濤、翟曉楓決定放棄對大安製藥的優先增資權。
公司主營業務為化工產品生產和銷售,大安製藥主要從事血液製品的生產和銷售,兩者行業差異較大,公司本次對大安製藥的增資屬於跨行業投資,可能存在一定的投資風險。大安製藥2019年前三季度淨利潤為1391.18萬元,較2018年全年5949.93萬元下滑較大,大安製藥存在全年經營業績大幅下滑的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.